Last updated: August 26, 2026
Norpramin, the former U.S. brand for desipramine hydrochloride, is no longer a meaningful branded pharmaceutical asset. Its commercial role has shifted to low-cost generic desipramine, a tricyclic antidepressant used mainly in selected patients after newer antidepressants fail or are unsuitable. The product has no current biologic, biosimilar, or meaningful patent-driven growth profile. Financial exposure is concentrated in generic manufacturing, pharmacy supply, and niche clinical demand rather than branded sales.
What is Norpramin and who owns the product?
Norpramin is the brand name for desipramine hydrochloride, a secondary-amine tricyclic antidepressant. It inhibits norepinephrine reuptake and has a pharmacologic profile that differs from selective serotonin reuptake inhibitors such as sertraline, escitalopram, and fluoxetine.
| Attribute |
Norpramin |
| Active ingredient |
Desipramine hydrochloride |
| Drug class |
Tricyclic antidepressant |
| Original route |
Oral tablets |
| Historical strengths |
10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg |
| Primary historical use |
Major depressive disorder |
| U.S. regulatory pathway |
FDA-approved NDA product |
| Current commercial form |
Generic desipramine hydrochloride |
| Current branded status |
Norpramin is not a significant actively marketed U.S. brand |
| Biosimilar relevance |
None |
| Main commercial substitutes |
SSRIs, SNRIs, atypical antidepressants, other TCAs |
Norpramin was historically associated with pharmaceutical companies that owned or marketed the product after the original approval, including entities connected to the Sanofi-Aventis group. The commercial rights have little present strategic value because generic competition has removed branded pricing power.
What is the FDA regulatory status of Norpramin?
The FDA approved desipramine hydrochloride for depression through an older new drug application. The product is listed in FDA regulatory records under the Norpramin brand and has also been marketed through abbreviated new drug applications for generic desipramine hydrochloride.[1]
The branded product has been reported as discontinued from active commercial distribution in the United States. A product discontinuation does not necessarily mean the FDA determined that the drug was unsafe or ineffective. FDA records distinguish commercial discontinuation from withdrawal for safety or efficacy reasons.[2]
The current regulatory market is therefore defined by generic desipramine products rather than Norpramin-branded tablets.
What is the Orange Book status of Norpramin?
The Orange Book historically identified desipramine hydrochloride tablets and associated reference-listed-drug information. The principal commercial significance of the listing is now regulatory substitution and generic approval, not remaining brand exclusivity.[3]
The relevant market structure is:
- The historical Norpramin reference product.
- Generic desipramine hydrochloride tablets approved under ANDAs.
- Pharmacy substitution based on state law, payer formularies, and wholesaler availability.
Norpramin does not have a current exclusivity position comparable to a recently approved small-molecule drug. Any historical patents or regulatory exclusivities associated with the original product have expired or ceased to be commercially relevant.
When did Norpramin lose exclusivity?
Norpramin lost practical market exclusivity decades ago. Desipramine is an older small molecule, and generic versions have been available for many years. The relevant commercial event was not a recent patent cliff but the long-term transition from branded distribution to generic supply.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No current commercial relevance |
| Brand patent protection |
Expired or commercially immaterial |
| Formulation exclusivity |
No meaningful current barrier identified |
| Method-of-use exclusivity |
No meaningful current barrier identified |
| Generic competition |
Established |
| Biosimilar competition |
Not applicable |
No current branded exclusivity supports premium pricing for Norpramin. A generic manufacturer does not need to overcome a live commercial patent estate comparable to those associated with newer antidepressants.
What patents protect Norpramin and desipramine?
The original desipramine compound and early pharmaceutical disclosures are old and no longer provide enforceable commercial protection in the United States. Current value does not arise from active composition-of-matter patents.
What formulations are protected by Norpramin patents?
Norpramin was primarily supplied as immediate-release oral tablets. There is no widely recognized active U.S. formulation patent that creates a meaningful barrier to generic immediate-release desipramine tablets.
Potential technical issues for generic manufacturers include:
- Consistent assay and content uniformity at low tablet strengths.
- Control of impurities and degradation products.
- Bioequivalence across tablet strengths.
- Stability during manufacturing and storage.
- Reliable supply of desipramine hydrochloride active pharmaceutical ingredient.
- Compliance with current good manufacturing practice requirements.
These are manufacturing and regulatory execution issues, not durable patent barriers.
Are there method-of-use patents for desipramine?
No current method-of-use patent appears to create material exclusivity for the principal depression indication. Historical clinical use in conditions such as neuropathic pain, attention-related disorders, or enuresis does not automatically create enforceable market protection.
Off-label prescribing remains possible, but off-label use does not create FDA exclusivity. Physicians can prescribe generic desipramine without infringing a patent merely because the treatment is used for a non-label condition, subject to any valid and enforceable method claims.
How large is the Norpramin market?
The branded Norpramin market is effectively negligible compared with large antidepressant franchises. Public companies generally do not report Norpramin revenue as a separate product line, and the product is not a material contributor to the financial results of major pharmaceutical manufacturers.
The addressable market consists of a small pool of patients receiving desipramine, generally under specialist supervision. Demand is constrained by:
- Safety monitoring requirements.
- Anticholinergic effects.
- Orthostatic hypotension.
- Cardiac conduction and arrhythmia concerns.
- Overdose toxicity.
- Availability of newer antidepressants.
- Limited promotional activity.
- Prescriber preference for better-tolerated therapies.
Desipramine can remain clinically relevant because it is relatively noradrenergic and may be selected for patients with a particular prior treatment response or tolerability profile. Clinical relevance does not translate into large revenue.
What is the financial trajectory for Norpramin?
Norpramin’s financial trajectory is best described as a completed brand erosion cycle followed by a low-value generic tail.
Historical branded phase
During the branded phase, revenue would have depended on physician prescribing, sales-force promotion, formulary access, and the availability of competing antidepressants. These factors weakened as SSRIs and later SNRIs became standard first-line therapies.
Generic transition
Generic entry changed the economics in three ways:
- Unit prices declined sharply.
- Pharmacy substitution removed much of the brand’s prescriber-driven demand.
- Multiple suppliers competed for a narrow and price-sensitive market.
Current generic phase
Current revenue is distributed among generic manufacturers and wholesalers. The market likely produces recurring but modest sales, with profitability depending on manufacturing scale, API procurement, supply continuity, and channel contracts.
| Financial driver |
Current effect |
| Brand price premium |
Minimal or absent |
| Volume growth |
Limited |
| Generic price |
Low |
| Gross margin |
Sensitive to scale and supply costs |
| Promotional spending |
Minimal |
| Payer leverage |
High |
| Shortage risk |
More important than patent risk |
| Strategic value |
Portfolio filling or niche supply |
| Revenue disclosure |
Generally not separated publicly |
A precise Norpramin revenue figure cannot be derived from public manufacturer filings because branded and generic desipramine sales are not normally reported as standalone segments. Public financial analysis should therefore use prescription volume, average selling price, product availability, and manufacturer participation rather than rely on a reported Norpramin revenue line.
Which companies are competing in generic desipramine?
Generic desipramine has historically been supplied by multiple established generic companies. FDA approval records and commercial databases have included products associated with companies such as Mylan, Sandoz, and other generic manufacturers over time.[1][4]
Supplier participation can change because of:
- Low market volume.
- API cost changes.
- Contract manufacturing decisions.
- Product rationalization.
- FDA inspection outcomes.
- Wholesale purchasing agreements.
- Temporary manufacturing interruptions.
The practical competitive landscape is narrower than the number of historical ANDA approvals suggests. Some approved products may be inactive, unavailable, or commercially insignificant.
What generic entry risks exist for Norpramin?
Generic entry risk is no longer a future event for Norpramin. It is the defining condition of the market.
The principal risks to any remaining branded or authorized distributor are:
- Permanent substitution by generic desipramine.
- No ability to sustain a meaningful price premium.
- Low patient switching costs at the pharmacy level.
- Payer preference for the lowest-cost product.
- Limited prescriber awareness of the historical brand.
- Product discontinuation if sales do not support manufacturing costs.
For generic manufacturers, the risk profile is different. The core threat is not patent litigation but margin compression and supply disruption. A manufacturer may hold an approved product yet decide that the commercial opportunity is too small to justify continued production.
Is Norpramin subject to Paragraph IV challenges?
Paragraph IV litigation is not a current strategic issue for the historical Norpramin brand. Paragraph IV certifications are relevant when an ANDA applicant challenges a listed patent. Because desipramine’s principal patent estate is old and no meaningful current brand exclusivity is evident, a new Paragraph IV dispute would not normally determine market entry.
Potential litigation would be more likely to involve:
- Product liability claims.
- Manufacturing or quality disputes.
- Distribution agreements.
- Patent assertions involving a newly developed formulation.
- Regulatory disputes over ANDA approval or product status.
No major recent U.S. patent litigation campaign is associated with ordinary immediate-release generic desipramine tablets in the public record reviewed for this analysis.
What litigation and settlement agreements affect Norpramin?
Norpramin is not associated with a current high-value patent settlement framework comparable to major branded drugs approaching generic entry. There is no commercially important settlement structure that controls current desipramine availability.
The absence of litigation is consistent with the product’s economics. A patent case is difficult to justify where:
- The reference product is old.
- Generic supply is established.
- Market revenue is limited.
- No high-value formulation or delivery platform is involved.
- The brand owner has little remaining commercial exposure.
How does Norpramin compare with newer antidepressants?
| Drug category |
Examples |
Commercial position versus desipramine |
| SSRIs |
Sertraline, fluoxetine, escitalopram |
Larger patient base and stronger first-line use |
| SNRIs |
Venlafaxine, duloxetine, desvenlafaxine |
Broader modern prescribing and higher commercial relevance |
| Atypical antidepressants |
Bupropion, mirtazapine, vortioxetine |
Differentiated tolerability or mechanism |
| Other TCAs |
Amitriptyline, nortriptyline, imipramine |
Compete in specialist and off-label uses |
| Desipramine |
Generic desipramine |
Niche use, low price, limited promotion |
Desipramine has a narrower commercial position because its tolerability and overdose profile are less favorable than those of many newer alternatives. Its relatively selective noradrenergic activity can support continued clinical use, but this is insufficient to create broad market expansion.
What geographic markets remain relevant?
The United States is no longer a branded Norpramin growth market. Generic desipramine may remain available in the U.S. through ANDA holders, subject to product status and supply.
Outside the United States, brand names, marketing rights, reimbursement, and availability vary by country. Desipramine may be sold under generic or local brand names, or may have limited availability. International opportunity is constrained by the same factors that limit U.S. growth:
- Older therapeutic class.
- Generic pricing.
- Small prescriber base.
- Local registration requirements.
- Limited promotional return.
- Competition from newer antidepressants.
Geographic expansion would require a low-cost regulatory and supply model rather than a conventional branded launch.
How strong is the Norpramin patent estate?
The patent estate is weak from a current commercial perspective.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Active formulation patents |
No material barrier identified |
| Method-of-use protection |
No material barrier identified |
| Generic entry barrier |
Low |
| Manufacturing complexity |
Low to moderate |
| Regulatory complexity |
Standard small-molecule ANDA requirements |
| Litigation leverage |
Low |
| Commercial pricing power |
Very low |
| Lifecycle-management potential |
Limited |
The strongest defensible assets are operational rather than legal: reliable API access, manufacturing quality, regulatory compliance, and dependable pharmacy supply.
What is the outlook for Norpramin revenue?
Norpramin-branded revenue should remain negligible unless a company deliberately reintroduces the brand for a narrowly defined specialty market. Such a strategy would face substantial obstacles:
- Generic substitution.
- Limited brand recognition among current prescribers.
- Little clinical differentiation.
- Reimbursement resistance.
- Safety-related prescribing constraints.
- High commercial cost relative to expected demand.
Generic desipramine revenue is more durable but remains small. The likely trajectory is stable-to-declining nominal revenue, interrupted by temporary price increases during supply shortages or supplier exits. Any price increase would reflect constrained supply rather than stronger underlying demand.
Key Takeaways
- Norpramin is the historical brand for desipramine hydrochloride.
- The U.S. brand has no meaningful current commercial position.
- Generic desipramine is the relevant market product.
- Composition, formulation, and method-of-use exclusivities do not create a material current barrier.
- Paragraph IV litigation and patent settlements are not significant current risks.
- Biosimilar competition is irrelevant because desipramine is a small molecule.
- Revenue is not publicly disclosed as a standalone line and is likely modest.
- The main commercial risks are low volume, price compression, supplier exits, and manufacturing interruptions.
- The product’s residual value is operational and clinical, not patent-based.
- Newer antidepressants control the large-volume market, while desipramine remains a specialist and niche generic therapy.
FAQs
Is Norpramin still available by prescription?
Generic desipramine hydrochloride may be available by prescription, while Norpramin-branded distribution is not a meaningful current U.S. channel. Availability can vary by manufacturer, pharmacy, and dosage strength.
Does desipramine have any remaining FDA exclusivity?
No commercially meaningful FDA exclusivity remains associated with ordinary generic desipramine tablets.
Can a company relaunch Norpramin as a premium brand?
A relaunch is legally possible if regulatory requirements are met, but commercial prospects are limited by generic substitution, low clinical differentiation, and payer resistance.
Is desipramine vulnerable to drug shortages?
Yes. Low-volume generic products can become vulnerable when manufacturers discontinue a strength, encounter production problems, or face API and packaging constraints. Supply risk is more relevant than patent risk.
Could a long-acting desipramine formulation create new value?
Potentially, but a new formulation would require regulatory approval and evidence supporting safety, efficacy, and bioequivalence or clinical benefit. Any value would arise from the new delivery system, not from Norpramin’s historical patent estate.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs - Desipramine hydrochloride and Norpramin records. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). FDA drug establishment and product status records. https://www.fda.gov/drugs
-
National Library of Medicine. (n.d.). DailyMed: Desipramine hydrochloride drug labels. https://dailymed.nlm.nih.gov/dailymed/
